ESC Premium Access

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Topic: Lipids (Epidemiology and Prevention)

Congress Session

About the speaker

Doctor Robert Giugliano

Brigham and Women's Hospital, Boston (United States of America)
9 presentations
0 follower

5 more presentations in this session

Increased all-cause mortality with intensive blood-pressure control in patients with a baseline systolic blood pressure of >=160 mmHg and a Lower Framingham risk score: a cautionary note from SPRINT

Speaker: Professor T. Wang (Taipei, TW)


Systolic Blood Pressure Variability and Major Adverse Outcomes in Patients with Atrial Fibrillation: the AFFIRM Study

Speaker: Doctor M. Proietti (Milan, IT)


The long-term efficacy and safety of short dual antiplatelet therapy

Speaker: Professor M. Nakamura (Tokyo, JP)


Mechanisms for the benefit of spironolactone in resistant hypertension in the PATHWAY-2 study

Speaker: Professor B. Williams (London, GB)


Aldosterone Lethal Effects Blocked in Acute Myocardial Infarction Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up

Speaker: Professor F. Beygui (Caen, FR)


Access the full session

Clinical Trial Update 1

Speakers: Doctor R. Giugliano, Professor T. Wang, Doctor M. Proietti, Professor M. Nakamura, Professor B. Williams...

About the event



26 August - 30 August 2017

Sessions Presentations

Related content

Open Access

Live discussion: The new ESC Heart Failure guidelines & potassium binding: What will change?

30 August 2021

ESC Premium Access

Cardiovascular benefit of lowering LDL-C below 1 mmol/L (40 mg/dl)

28 August 2021

Open Access

New recommendations for the treatment of HFrEF.

27 August 2021

This platform is supported by

logo Novo Nordisk